145 related articles for article (PubMed ID: 9291807)
1. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Pappot H; Høyer-Hansen G; Rønne E; Hansen HH; Brünner N; Danø K; Grøndahl-Hansen J
Eur J Cancer; 1997 May; 33(6):867-72. PubMed ID: 9291807
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Cobos E; Jumper C; Lox C
Clin Appl Thromb Hemost; 2003 Jul; 9(3):241-6. PubMed ID: 14507113
[TBL] [Abstract][Full Text] [Related]
4. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
5. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
6. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Salden M; Splinter TA; Peters HA; Look MP; Timmermans M; van Meerbeeck JP; Foekens JA
Ann Oncol; 2000 Mar; 11(3):327-32. PubMed ID: 10811500
[TBL] [Abstract][Full Text] [Related]
7. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
Int J Cancer; 1997 Jul; 72(3):416-23. PubMed ID: 9247284
[TBL] [Abstract][Full Text] [Related]
8. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Pappot H; Skov BG; Pyke C; Grøndahl-Hansen J
Lung Cancer; 1997 Jul; 17(2-3):197-209. PubMed ID: 9237155
[TBL] [Abstract][Full Text] [Related]
9. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
12. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
13. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
14. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
15. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
16. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Holst-Hansen C; Hamers MJ; Johannessen BE; Brünner N; Stephens RW
Br J Cancer; 1999 Sep; 81(2):203-11. PubMed ID: 10496343
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
[TBL] [Abstract][Full Text] [Related]
18. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
